CLINICAL_TRIALS
trial_result
· 2022-09-01
Clinical Trial Update: A Study of Olverembatinib in the Treatment of Ph+ ALL [Phase 2]
Summary
Phase 2 clinical trial update for Olverembatinib in treating Philadelphia-Positive acute lymphoblastic leukemia (Ph+ ALL).
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Chen Suning | Conditions: Philadelphia-Positive ALL | Phase 2 | Status: UNKNOWN